Total Payments
$263,551
2024 Payments
$54,593
Companies
11
Transactions
137
Payment Breakdown by Category
Research$183,166 (69.5%)
Consulting$72,210 (27.4%)
Travel$6,404 (2.4%)
Food & Beverage$1,770 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $183,166 | 78 | 69.5% |
| Consulting Fee | $72,210 | 13 | 27.4% |
| Travel and Lodging | $6,404 | 25 | 2.4% |
| Food and Beverage | $1,770 | 21 | 0.7% |
Payments by Type
Research
$183,166
78 transactions
General
$80,384
59 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $177,326 | 33 | $0 (2024) |
| US WorldMeds, LLC | $72,210 | 13 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $6,393 | 47 | $0 (2023) |
| Allergan Inc. | $2,685 | 11 | $0 (2018) |
| Jazz Pharmaceuticals Inc. | $1,562 | 3 | $0 (2023) |
| PFIZER INC. | $1,413 | 5 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $949.64 | 9 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $746.05 | 8 | $0 (2017) |
| Dr.Reddy's Laboratories,Inc. | $140.79 | 4 | $0 (2017) |
| Eisai Inc. | $80.10 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,593 | 9 | Eli Lilly and Company ($54,593) |
| 2023 | $13,158 | 27 | Eli Lilly and Company ($10,723) |
| 2022 | $112,029 | 7 | Eli Lilly and Company ($112,010) |
| 2020 | $3,334 | 39 | Takeda Pharmaceuticals U.S.A., Inc. ($3,334) |
| 2019 | $17,092 | 22 | US WorldMeds, LLC ($13,864) |
| 2018 | $60,865 | 15 | US WorldMeds, LLC ($58,347) |
| 2017 | $2,479 | 18 | Allergan Inc. ($1,592) |
All Payment Transactions
137 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,663.00 | Research |
| Study: PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $21,321.00 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $17,455.00 | Research |
| Study: A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $10,731.21 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | ||||||
| 06/06/2024 | Eli Lilly and Company | — | — | In-kind items and services | $465.76 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY | ||||||
| 04/05/2024 | Eli Lilly and Company | — | — | In-kind items and services | $308.19 | Research |
| Study: A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | ||||||
| 03/19/2024 | Eli Lilly and Company | — | — | In-kind items and services | $84.08 | Research |
| Study: PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | ||||||
| 03/19/2024 | Eli Lilly and Company | — | — | In-kind items and services | $39.91 | Research |
| Study: A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | ||||||
| 01/18/2024 | Eli Lilly and Company | — | — | In-kind items and services | $524.71 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | ||||||
| 11/13/2023 | Eli Lilly and Company | — | — | In-kind items and services | $213.77 | Research |
| Study: PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | ||||||
| 11/13/2023 | Eli Lilly and Company | — | — | In-kind items and services | $16.46 | Research |
| Study: A MASTER PROTOCOL FOR A RANDOMIZED CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | ||||||
| 09/26/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $1,084.20 | General |
| 09/26/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $488.91 | General |
| 09/26/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $164.00 | General |
| 09/26/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $157.38 | General |
| 09/26/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $88.72 | General |
| 09/26/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $75.88 | General |
| 09/26/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $70.97 | General |
| 09/26/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $59.27 | General |
| 09/26/2023 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $50.72 | General |
| 09/26/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $25.01 | General |
| 09/26/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $11.01 | General |
| 09/26/2023 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $10.00 | General |
| 07/20/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | In-kind items and services | $58.19 | Research |
| Study: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) | ||||||
| 06/09/2023 | Eli Lilly and Company | — | — | In-kind items and services | $2,581.54 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | Eli Lilly and Company | $52,666 | 3 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA) | Eli Lilly and Company | $42,271 | 3 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | Eli Lilly and Company | $22,698 | 3 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY | Eli Lilly and Company | $21,787 | 2 |
| A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | Eli Lilly and Company | $17,763 | 2 |
| A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) | Eli Lilly and Company | $13,837 | 3 |
| PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | Eli Lilly and Company | $3,961 | 3 |
| A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) | Takeda Pharmaceuticals U.S.A., Inc. | $2,252 | 6 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) | Takeda Pharmaceuticals U.S.A., Inc. | $1,904 | 20 |
| A PHASE 1B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSSOVER STUDY OF 2 SINGLE INTRAVENOUS INFUSION DOSES OF TAK-925 IN SUBJECTS WITH OBSTRUCTIVE SLEEP APNEA WHO ARE EXPERIENCING EXCESSIVE DAYTIME SLEEPINESS DESPITE ADEQUATE USE OF CPAP | Takeda Pharmaceuticals U.S.A., Inc. | $1,169 | 14 |
| A Phase 1b Randomized, Double-blind, Placebo-Controlled, Crossover Study of 2 Single Intravenous Infusion Doses of TAK-925 in Subjects With Obstructive Sleep Apnea Who Are Experiencing Excessive Daytime Sleepiness Despite Adequate Use of CPAP | Takeda Pharmaceuticals U.S.A., Inc. | $806.72 | 2 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $796.00 | 3 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $796.00 | 3 |
| A STUDY TO ASSESS THE FREQUENCY AND CHARACTERISTICS OF WAKE AND SLEEP STATE TRANSITIONS OVER MULTIPLE NIGHTS IN SUBJECTS WITH NARCOLEPSY TYPE 1 COMPARED WITH HEALTHY SUBJECTS USING A PORTABLE ELECTROENCEPHALOGRAM DEVICE | Takeda Pharmaceuticals U.S.A., Inc. | $261.26 | 5 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura Oral Celecoxib | Dr.Reddy's Laboratories,Inc. | $140.79 | 4 |
| A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | Eli Lilly and Company | $39.91 | 1 |
| A MASTER PROTOCOL FOR A RANDOMIZED CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | Eli Lilly and Company | $16.46 | 1 |
About Dr. James Maynard, M.D
Dr. James Maynard, M.D is a Neurology healthcare provider based in Fort Thomas, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942229166.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Maynard, M.D has received a total of $263,551 in payments from pharmaceutical and medical device companies, with $54,593 received in 2024. These payments were reported across 137 transactions from 11 companies. The most common payment nature is "" ($183,166).
Ad
Practice Information
- Specialty Neurology
- Other Specialties Sleep Medicine, Specialist
- Location Fort Thomas, KY
- Active Since 07/19/2006
- Last Updated 11/09/2010
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1942229166
Products in Payments
- APOKYN (Drug) $72,210
- PREVNAR - 13 (Biological) $1,413
- XYREM (Drug) $202.80
- QUVIVIQ (Drug) $44.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.